Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion
Bertrand Tombal(Cliniques Universitaires Saint-Luc), Herman Stoevelaar(Barnes-Jewish Hospital), Bianca Meesen(Exmar (Belgium)), Mesut Remzi(Landesklinikum Korneuburg), Paolo Gontero(Fondazione Ricerca Molinette), Filip Ameye(Universitair Ziekenhuis Leuven), Alessandro Volpe(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paul B. Perrin(University of Virginia), Alexander Haese(Universität Hamburg), Jörg Schröder(Praxis für Hämatologie und Onkologie), Paul J.M. Kil(Andros Clinica Day Surgery), Theo de Reijke(Amsterdam UMC Location University of Amsterdam), Alexandre de la Taille(Centre Hospitalier Universitaire Henri-Mondor), Mark Speakman(Taunton & Somerset NHS Foundation Trust)
Cited by 19
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
|European Urology|2015|578